Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Clin Chim Acta. 2017 Dec;475:137-146. doi: 10.1016/j.cca.2017.10.013. Epub 2017 Oct 16.
Gestational diabetes mellitus (GDM) is harmful to both the mother and fetus. Although transplantation of human umbilical cord mesenchymal stem cells (HUMSCs) could be a useful therapy for GDM, the influences of different transplantation routes on the therapeutic effects remain unclear. In this study, we isolated and cultured the HUMSCs for transplantation, and the biological activity of HUMSCs was verified by flow cytometric analysis (the positive markers, CD44, CD73, CD105 and CD90, the negative markers, CD45, CD34, CD19, HLA-DR, and CD11b) and potency of osteogenic, adipogenic and chondrogenic differentiation. Streptozotocin (STZ)-induced diabetes mellitus (DM)/GDM rats were transplanted with HUMSCs by different routes: single or multiple tail vein injection, liver parenchyma, and renal capsule transplantation. These were compared to positive controls (STZ-induced, untreated) and negative controls (non-induced, untreated) to determine the effect of the transplant on the control of DM/GDM. The blood glucose level and body weight of rats in each group were determined and showed different effects. Transplantation of HUMSCs to GDM rats can increase the number of offspring in comparison to the negative controls. The weight of the offspring in the transplantation groups also increased due to the therapeutic effect of HUMSCs. Based on results, we concluded that transplanting HUMSCs could effectively alleviate the symptoms of elevated blood glucose and weight loss and improve the body weight and survival rate of offspring. Injections of HUMSCs were required to persistently decrease the blood glucose of DM and GDM rats. Transplanting HUMSCs into the liver or renal capsule of GDM rats led to a similar efficiency of controlling blood glucose and compensation for body weight. HUMSCs therapy increased the number and body weight of offspring and improved their activity. In summary, this study has enabled progress toward determining the optimal route for GDM therapy.
妊娠期糖尿病(GDM)对母婴均有害。尽管人脐带间充质干细胞(HUMSCs)移植可能是治疗 GDM 的一种有用方法,但不同移植途径对治疗效果的影响尚不清楚。在本研究中,我们分离和培养了 HUMSCs 进行移植,并通过流式细胞术分析(阳性标志物 CD44、CD73、CD105 和 CD90,阴性标志物 CD45、CD34、CD19、HLA-DR 和 CD11b)和成骨、成脂和成软骨分化的能力验证了 HUMSCs 的生物学活性。链脲佐菌素(STZ)诱导的糖尿病(DM)/GDM 大鼠通过不同途径(单次或多次尾静脉注射、肝实质和肾包膜移植)移植 HUMSCs,并与阳性对照(STZ 诱导、未治疗)和阴性对照(未诱导、未治疗)进行比较,以确定移植对 DM/GDM 控制的影响。测定各组大鼠血糖水平和体重,显示出不同的效果。与阴性对照组相比,HUMSCs 移植到 GDM 大鼠可增加后代的数量。由于 HUMSCs 的治疗作用,移植组后代的体重也增加了。基于这些结果,我们得出结论,移植 HUMSCs 可以有效缓解高血糖和体重减轻的症状,并改善后代的体重和存活率。HUMSCs 注射需要持续降低 DM 和 GDM 大鼠的血糖。将 HUMSCs 移植到 GDM 大鼠的肝或肾包膜中,对控制血糖和补偿体重的效果相似。HUMSCs 治疗增加了后代的数量和体重,并提高了它们的活动能力。总之,本研究为确定 GDM 治疗的最佳途径取得了进展。